Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fernanda Amary

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Medical Imaging and Radiation Oncology|February 14, 2015
Gout-mimicking sarcoma recurrence at a prosthesis bone interface remote from any jointBamikole Busayo Kenneth Ogunwale, M Fernanda Amary, John Andrew Mcinnes Skinner, et al.
Skeletal Radiology|February 6, 2013
Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five casesM Fernanda Amary, Paul O'Donnell, Fitim Berisha, et al.
Virchows Archiv : an International Journal of Pathology|November 30, 2014
Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomasM Fernanda Amary, Hongtao Ye, Georgina Forbes, et al.
Virchows Archiv : an International Journal of Pathology|April 4, 2015
Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatosesSarah J Aitken, Nadège Presneau, Sangeetha Kalimuthu, et al.
Histopathology|February 5, 2016
The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastomaM Fernanda Amary, Fitim Berisha, Rafael Mozela, et al.
The Journal of Pathology. Clinical Research|August 9, 2016
Clinical outcome in patients with peripherally-sited atypical lipomatous tumours and dedifferentiated liposarcomaSangeetha N Kalimuthu, Charles Tilley, Georgina Forbes, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2015
GNAS mutations are not detected in parosteal and low-grade central osteosarcomasCarolina Salinas-Souza, Carlos De Andrea, Michel Bihl, et al.
The Journal of Pathology|May 21, 2011
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumoursM Fernanda Amary, Krisztian Bacsi, Francesca Maggiani, et al.
Nature Communications|July 19, 2013
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2Paul Guilhamon, Malihe Eskandarpour, Dina Halai, et al.
Cancer Medicine|May 28, 2014
Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapyM Fernanda Amary, Hongtao Ye, Fitim Berisha, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Medical Imaging and Radiation Oncology|February 14, 2015
Gout-mimicking sarcoma recurrence at a prosthesis bone interface remote from any jointBamikole Busayo Kenneth Ogunwale, M Fernanda Amary, John Andrew Mcinnes Skinner, et al.
Skeletal Radiology|February 6, 2013
Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five casesM Fernanda Amary, Paul O'Donnell, Fitim Berisha, et al.
Virchows Archiv : an International Journal of Pathology|November 30, 2014
Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomasM Fernanda Amary, Hongtao Ye, Georgina Forbes, et al.
Virchows Archiv : an International Journal of Pathology|April 4, 2015
Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatosesSarah J Aitken, Nadège Presneau, Sangeetha Kalimuthu, et al.
Histopathology|February 5, 2016
The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastomaM Fernanda Amary, Fitim Berisha, Rafael Mozela, et al.
The Journal of Pathology. Clinical Research|August 9, 2016
Clinical outcome in patients with peripherally-sited atypical lipomatous tumours and dedifferentiated liposarcomaSangeetha N Kalimuthu, Charles Tilley, Georgina Forbes, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2015
GNAS mutations are not detected in parosteal and low-grade central osteosarcomasCarolina Salinas-Souza, Carlos De Andrea, Michel Bihl, et al.
The Journal of Pathology|May 21, 2011
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumoursM Fernanda Amary, Krisztian Bacsi, Francesca Maggiani, et al.
Nature Communications|July 19, 2013
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2Paul Guilhamon, Malihe Eskandarpour, Dina Halai, et al.
Cancer Medicine|May 28, 2014
Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapyM Fernanda Amary, Hongtao Ye, Fitim Berisha, et al.
Pageof 2